Skip to main content

Table 3 Antitumour activity in evaluable patients

From: A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

Dose of epertinibArm AArm BArm C 
Epertinib + TEpertinib + T + VEpertinib + T + C 
400mg600mg800mg200mg400mg200mg400mg600mgOverall
N=5N=9N=7N=5N=2N=4N=9N=4N=45
BOR
 CR000000000
 PR06 (66.7%)1 (14.3%)02 (100%)05 (55.6%)2 (50.0%)16 (35.6%)
 SD ≥ 6 months2 (40.0%)01 (14.3%)4 (80.0%)01 (25.0%)01 (25.0%)9 (20.0%)
 CBR2 (40.0%)6 (66.7%)2 (28.6%)4 (80.0%)2 (100%)1 (25.0%)5 (55.6%)3 (75.0%)25 (55.6%)
 PD2 (40.0%)1 (11.1%)2 (28.6%)001 (25.0%)1 (11.1%)1 (25.0%)8 (17.8%)
  1. Clinical benefit is defined as objective response plus SD at 6 months
  2. Abbreviations: T trastuzumab, V vinorelbine, C capecitabine, BOR best overall response, CR complete response, PR partial response, SD stable disease, CBR clinical benefit rate, PD progressive disease